GlassScriptPhysician profile
Andrea Dawn Carpenter
NPI 1336794650
$7,491.58
in general payments reported to CMS, 2019-2025
42 companies · $2,320 in 2025
The $2,320 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,838 · 2022: $1,120 · 2023: $1,004 · 2024: $1,210 · 2025: $2,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,605 · Education: $491 · Consulting Fee: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,605.30 |
| Education | $490.79 |
| Consulting Fee | $437.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,675.22 | 2021-2025 | Tagrisso, Lynparza, Datroway |
| Abbvie INC. | $1,329.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $437.79 | 2021-2025 | Jemperli, Zejula |
| Astellas Pharma US INC | $425.29 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $345.26 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Merck Sharp & Dohme LLC | $276.18 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $247.59 | 2023-2025 | Padcev, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $229.19 | 2021-2025 | Cinryze, Ninlaro, Fruzaqla |
| Pfizer INC. | $217.59 | 2021-2025 | |
| Incyte Corporation | $211.41 | 2023-2025 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.66 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $179.03 | 2022-2025 | Libtayo, Dupixent |
| Eisai INC. | $176.65 | 2021-2025 | |
| Lilly USA, LLC | $176.12 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $168.23 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.